UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000053256 |
|---|---|
| Receipt number | R000060777 |
| Scientific Title | Meta-analysis on diagnosis and treatment of pulmonary artery sarcoma |
| Date of disclosure of the study information | 2024/01/01 |
| Last modified on | 2024/12/25 19:12:25 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Meta analysis of pulmonary artery sarcoma
Acronym
Meta-analysis on diagnosis and treatment of pulmonary artery sarcoma
Scientific Title
Meta-analysis on diagnosis and treatment of pulmonary artery sarcoma
Scientific Title:Acronym
Meta-analysis on diagnosis and treatment of pulmonary artery sarcoma
Region
| Japan | Asia(except Japan) | North America |
| South America | Australia | Europe |
| Africa |
Condition
Condition
Primary pulmonary artery sarcoma
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
Mainly through meta-analysis, we will analyze the diagnosis and treatment of pulmonary artery sarcoma.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Clinical features of primary pulmonary artery sarcoma
Key secondary outcomes
Response rate and survival by treatment modality in pulmonary artery sarcoma
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients with pulmonary artery sarcoma
Key exclusion criteria
Patients with undiagnosed pulmonary artery sarcoma
Target sample size
400
Research contact person
Name of lead principal investigator
| 1st name | Fumihiro |
| Middle name | |
| Last name | Kashizaki |
Organization
Yokohama Minami Kyosai Hospital
Division name
Department of Respiratory Medicine
Zip code
2360037
Address
1-21-1 Mutsuura Higashi, Kanazawa Ward, Yokohama City, Kanagawa
TEL
+81-45-782-2101
f.kashizaki@gmail.com
Public contact
Name of contact person
| 1st name | Fumiiro |
| Middle name | |
| Last name | Kashizaki |
Organization
Yokohama Minami Kyosai Hospital
Division name
Department of Respiratory Medicine
Zip code
2360037
Address
1-21-1 Mutsuura Higashi, Kanazawa Ward, Yokohama City, Kanagawa
TEL
0457822101
Homepage URL
f.kashizaki@gmail.com
Sponsor or person
Institute
Yokohama Minami Kyosai Hospital
Institute
Department
Personal name
Funding Source
Organization
No financial support was provided.
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
The Ethics Committee at Yokohama Minami Kyosai Hospital
Address
1-21-1 Mutsuura Higashi, Kanazawa Ward, Yokohama City, Kanagawa
Tel
+81457822101
f.kashizaki@gmail.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2024 | Year | 01 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
https://www.archbronconeumol.org/es-pdf-S0300289624004848
Number of participants that the trial has enrolled
643
Results
Overall, 643 patients were included (mean age: 52.6 years, 50.4% were female).70.6% were diagnosed with pulmonary thromboembolism (PTE), and 15.4% were suspected of having PPAS. Among these, 93.9% and 55.2% showed suggestive findings on 18F-FDG PET/CT and CT, respectively. The right main pulmonary artery was the most affected site on CT (72.3%). Surgery and chemotherapy were performed in 81.4% and 66.4% of patients, respectively. The median OS was 31 months.
Results date posted
| 2024 | Year | 12 | Month | 25 | Day |
Results Delayed
| Delay expected |
Results Delay Reason
The analysis was underway, but was completed in December 2024.
Date of the first journal publication of results
| 2024 | Year | 12 | Month | 20 | Day |
Baseline Characteristics
643 patients were included (mean age: 52.6 +/- 13.1 years; 50.4% were female).
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2024 | Year | 01 | Month | 01 | Day |
Date of IRB
| 2024 | Year | 01 | Month | 01 | Day |
Anticipated trial start date
| 2024 | Year | 01 | Month | 01 | Day |
Last follow-up date
| 2024 | Year | 01 | Month | 02 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Data collection completed for Meta analysis.
Management information
Registered date
| 2024 | Year | 01 | Month | 01 | Day |
Last modified on
| 2024 | Year | 12 | Month | 25 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060777
